A groundbreaking strategic collaboration between Thermo Fisher Scientific and Arcturus Therapeutics is set to significantly advance the development and potential commercialization of ARCT-032, an innovative messenger RNA (mRNA) therapy targeting cystic fibrosis (CF). This comprehensive partnership leverages Thermo Fisher’s extensive capabilities in integrated manufacturing, clinical research, and commercial readiness, aiming to streamline the path for ARCT-032 from late-stage clinical trials to patient accessibility.
Main Facts:
Thermo Fisher Scientific, a global leader in serving science, has entered into a strategic collaboration agreement with Arcturus Therapeutics, a leading mRNA medicines company. The core objective of this partnership is to support the Phase III development of ARCT-032, a promising mRNA therapy designed to treat cystic fibrosis. Beyond clinical development, the collaboration also encompasses strategies for the potential commercialization of this investigational therapy.
At the heart of this alliance lies Thermo Fisher’s Accelerator Drug Development solutions. This integrated offering is designed to provide end-to-end support for drug development programs, encompassing everything from early-stage manufacturing to late-stage clinical trials and eventual market launch. By engaging Thermo Fisher’s Accelerator program, Arcturus Therapeutics aims to expedite the crucial development phases of ARCT-032.
The agreement outlines a phased approach. If ARCT-032 demonstrates positive outcomes in its ongoing Phase II clinical trials, Arcturus Therapeutics plans to entrust the execution of its Phase III clinical program to Thermo Fisher’s renowned PPD clinical research business. This move signifies a strong endorsement of PPD’s expertise in managing complex, global clinical trials.
Furthermore, subject to the necessary regulatory approvals, Thermo Fisher Scientific is poised to secure exclusive commercial manufacturing rights for ARCT-032 under a future commercial agreement. This forward-looking provision underscores Thermo Fisher’s commitment to supporting the therapy throughout its lifecycle, from clinical development to large-scale production and distribution.
Chronology of the Collaboration:
While the exact date of the agreement’s signing is not specified, the announcement signifies a crucial juncture in the development journey of ARCT-032. The collaboration is strategically timed to align with the anticipated positive results from Arcturus’s Phase II trials, paving the way for the imminent commencement of Phase III studies.
The collaboration’s structure implies a sequential progression:
- Phase II Clinical Trials (Ongoing): Arcturus Therapeutics is currently conducting Phase II trials for ARCT-032. The success of these trials is a critical prerequisite for the progression into Phase III.
- Phase III Clinical Program: Upon successful completion of Phase II, Thermo Fisher’s PPD clinical research business will assume responsibility for managing and executing the extensive Phase III clinical trials. This will involve a global network of trial sites and a rigorous data collection and analysis process.
- Commercial Manufacturing: Concurrently, Thermo Fisher will be positioned to become the exclusive commercial manufacturer of ARCT-032, contingent on regulatory approvals and the finalization of a commercial agreement. This ensures a seamless transition from clinical supply to market availability.
- Potential Commercialization: The overarching goal of the collaboration is to facilitate the successful commercial launch and widespread accessibility of ARCT-032 to patients suffering from cystic fibrosis.
This phased approach allows for a risk-mitigated and efficient progression, ensuring that all necessary steps are taken to bring this potentially life-changing therapy to market.
Supporting Data and Scientific Rationale:
Cystic fibrosis (CF) is a rare, inherited genetic disorder that causes severe damage to the lungs, digestive system, and other organs. It affects more than 100,000 people in North America, Europe, and Australia. The disease is characterized by the buildup of thick, sticky mucus that can clog airways and lead to chronic lung infections, breathing difficulties, and progressive lung damage. It also affects the pancreas, leading to digestive problems and malnutrition.
Messenger RNA (mRNA) technology has emerged as a revolutionary platform for developing novel therapeutics. Unlike traditional gene therapies that alter a patient’s DNA, mRNA therapies deliver instructions to cells to produce specific proteins. In the case of ARCT-032, the mRNA molecule is designed to instruct lung cells to produce functional CFTR protein, the absence or malfunction of which is the root cause of cystic fibrosis.
ARCT-032 is an inhaled lipid-nanoparticle (LNP)-formulated mRNA therapeutic. The LNP technology is crucial for protecting the fragile mRNA molecule and facilitating its delivery into target cells within the lungs. By enabling the production of functional CFTR protein, ARCT-032 aims to address the underlying cause of CF, offering a potential disease-modifying treatment rather than just symptomatic relief.
The decision by Arcturus Therapeutics to partner with Thermo Fisher Scientific for Phase III development and commercialization is informed by the latter’s extensive experience and robust infrastructure in the biopharmaceutical industry. Thermo Fisher’s Accelerator Drug Development solutions offer a comprehensive suite of services that are critical for navigating the complexities of late-stage drug development. These include:
- Integrated Manufacturing: The ability to scale up the production of mRNA and LNP formulations under stringent Good Manufacturing Practice (GMP) conditions is paramount. Thermo Fisher’s expertise in contract development and manufacturing organization (CDMO) services ensures a reliable and high-quality supply of ARCT-032 for clinical trials and eventual commercial distribution.
- Clinical Research Expertise: Thermo Fisher’s PPD clinical research business is a globally recognized leader in managing clinical trials across various therapeutic areas. Their expertise in trial design, site selection, patient recruitment, data management, and regulatory compliance is vital for the successful execution of a large-scale Phase III program.
- Commercial Readiness: This encompasses a range of services crucial for market launch, including regulatory affairs support, supply chain logistics, market access strategies, and pharmacovigilance. By integrating these services, Thermo Fisher aims to ensure a smooth and efficient transition from clinical development to commercial availability.
Official Responses and Expert Commentary:
The strategic collaboration has been met with significant optimism from the leadership of both companies, highlighting the synergistic nature of their partnership.
Joseph Payne, President and CEO of Arcturus Therapeutics, expressed his enthusiasm for the collaboration, stating, "We are pleased to collaborate with Thermo Fisher to utilize its impressive CDMO capabilities, global infrastructure and proven ability to support complex mRNA programs from Phase III through potential commercialization. Their capabilities are aligned with Arcturus’s goal of efficiently advancing our cystic fibrosis program into Phase III and preparing for potential commercial supply." This statement underscores Arcturus’s recognition of Thermo Fisher’s end-to-end solutions and their alignment with Arcturus’s strategic objectives.
Mike Shafer, Executive Vice President and President of Thermo Fisher Biopharma Services, echoed these sentiments, emphasizing the growing need for integrated partners in the biopharmaceutical sector. "Biotechnology innovators increasingly seek strategic collaborators that can support complex development programs across clinical and commercial stages," Shafer commented. He further elaborated on the value proposition of Thermo Fisher’s integrated model: "Through Accelerator Drug Development, Thermo Fisher brings together manufacturing, clinical research and commercialization expertise to help customers simplify development, reduce operational complexity and accelerate the delivery of innovative therapies to patients. Our collaboration with Arcturus demonstrates the value of this integrated model." This highlights Thermo Fisher’s commitment to simplifying the drug development journey for its partners and accelerating the delivery of life-saving treatments.
The collaboration also aligns with broader trends in the pharmaceutical industry, where companies are increasingly relying on specialized partners to manage different stages of drug development. This allows smaller, innovative biotech firms to focus on their core competencies in research and discovery, while leveraging the extensive resources and expertise of larger service providers.
Implications of the Partnership:
The strategic collaboration between Thermo Fisher Scientific and Arcturus Therapeutics carries significant implications for the development of ARCT-032, the cystic fibrosis patient community, and the broader mRNA therapeutics landscape.
-
Accelerated ARCT-032 Development: The most immediate implication is the potential for a significantly accelerated development timeline for ARCT-032. By combining Arcturus’s innovative mRNA technology with Thermo Fisher’s integrated development and manufacturing capabilities, the journey from Phase III trials to potential market approval could be streamlined, bringing a much-needed therapy to patients sooner.
-
Enhanced Patient Access to Innovative Therapies: For individuals living with cystic fibrosis, this partnership offers a beacon of hope. The successful development and commercialization of ARCT-032 could provide a new, potentially disease-modifying treatment option, improving lung function, reducing exacerbations, and ultimately enhancing the quality of life for patients. The focus on commercial readiness ensures that if approved, the therapy will be accessible to those who need it.
-
Validation of Thermo Fisher’s Integrated Model: This collaboration serves as a powerful testament to the effectiveness of Thermo Fisher’s Accelerator Drug Development solutions. It demonstrates their ability to provide comprehensive, end-to-end support for complex therapeutic modalities like mRNA, solidifying their position as a key partner for biotech innovators.
-
Advancement of mRNA Therapeutics: The success of ARCT-032, supported by this robust partnership, could further validate the immense potential of mRNA technology beyond vaccines. It could pave the way for the development of other mRNA-based therapies for a wide range of genetic and acquired diseases, expanding the therapeutic landscape and offering new hope to patients with unmet medical needs.
-
Focus on Sustainability in Clinical Trials: It is noteworthy that Thermo Fisher, through its PPD business, has been actively promoting sustainability in clinical research. In October 2025, PPD introduced the Clinical Trial Carbon Calculator, an initiative designed to help sponsors minimize, estimate, and understand the environmental impact of their trials. This forward-thinking approach suggests that sustainability considerations may also be integrated into the ARCT-032 development program, aligning with growing global concerns for environmental responsibility in the pharmaceutical industry.
In conclusion, the strategic collaboration between Thermo Fisher Scientific and Arcturus Therapeutics represents a significant step forward in the fight against cystic fibrosis. By uniting cutting-edge mRNA science with unparalleled development and manufacturing expertise, this partnership is poised to accelerate the delivery of a potentially life-changing therapy to patients and further cement the transformative power of mRNA technology in modern medicine.
About the Author
